Sunday, June 05, 2022 7:11:18 PM
Biotechnology advances (2011-10-11)
Jean-Christophe Drugmand, Yves-Jacques Schneider, Spiros N Agathos
PMID21983546
ABSTRACT
Insect cells (IC) and particularly lepidopteran cells are an attractive alternative to mammalian cells for biomanufacturing. Insect cell culture, coupled with the lytic expression capacity of baculovirus expression vector systems (BEVS), constitutes a powerful platform, IC-BEVS, for the abundant and versatile formation of heterologous gene products, including proteins, vaccines and vectors for gene therapy. Such products can be manufactured on a large scale thanks to the development of efficient and scaleable production processes involving the integration of a cell growth stage and a stage of cell infection with the recombinant baculovirus vector. Insect cells can produce multimeric proteins functionally equivalent to the natural ones and engineered vectors can be used for efficient expression. Insect cells can be cultivated easily in serum- and protein-free media. A growing number of companies are currently developing an interest in producing therapeutics using IC-BEVS, and many products are today in clinical trials and on the market for veterinary and human applications. This review summarizes current knowledge on insect cell metabolism, culture conditions and applications.
https://www.sigmaaldrich.com/US/en/tech-docs/paper/154388
Recent MYMX News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 01/02/2024 06:16:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 01:00:38 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/13/2023 05:15:20 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 01:53:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2023 08:42:46 PM
- Form SC 13E3 - Going private transaction by certain issuers • Edgar (US Regulatory) • 10/17/2023 07:08:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/11/2023 01:00:41 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/18/2023 10:02:57 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2023 09:01:04 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM